AOD-9604 research guide

AOD-9604 in Kani — Fat Loss Peptide Research Guide

AOD-9604 research guide for Kani. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

AOD-9604 in Kani — Research & Sourcing Guide

AOD-9604 isn't available on pharmacy shelves in Kani or anywhere else for that matter — this is a specialist compound available through a dedicated online market. This matters because AOD-9604 quality varies dramatically across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor determines everything about the product. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis showing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. The sections below cover what Kani researchers need to know about finding, evaluating, and storing AOD-9604 for research purposes.

What Studies Say About AOD-9604

AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Kani studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.

Buying AOD-9604: Quality Markers to Look For

The most reliable path to quality AOD-9604 is starting with community forums — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are within acceptable research limits. Negative indicators in AOD-9604 vendor evaluation: prices more than 30-40% below standard market rates, vague sourcing information, no community presence, and COAs that do not include endotoxin results. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 30 days refrigerated.

Order AOD-9604 — ships to Kani
COA-verified · International tracking · Research grade
Order Now →

AOD-9604: Storage, Reconstitution & Safety

Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and consistent cold chain handling. Endotoxin testing in the AOD-9604 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at minute levels, and no pricing advantage justifies skipping this verification. The research literature on AOD-9604 should be read critically before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and results do not always generalise across models.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →